Clinical Trials
3 trialsNCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
NCT04079738 2023-09-13
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT03756818 2023-02-28
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed